335 related articles for article (PubMed ID: 26493618)
21. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
[TBL] [Abstract][Full Text] [Related]
22. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O
J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843
[TBL] [Abstract][Full Text] [Related]
23. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
Pillappa R; Maleszewski JJ; Sukov WR; Bedroske PP; Greipp PT; Boland JM; Yi ES; Peikert T; Aubry MC; Roden AC
Am J Surg Pathol; 2018 Feb; 42(2):256-263. PubMed ID: 29076876
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma.
Vivero M; Bueno R; Chirieac LR
Mod Pathol; 2018 Jan; 31(1):122-131. PubMed ID: 28884745
[TBL] [Abstract][Full Text] [Related]
25. Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Iwasaki A; Nabeshima K
Cancer Cytopathol; 2021 Jul; 129(7):526-536. PubMed ID: 33493384
[TBL] [Abstract][Full Text] [Related]
26. Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma.
Şeker NS; Tekin E; Ak G; Metintaş M; Metintaş S; Dündar E
Diagn Cytopathol; 2024 Apr; 52(4):211-216. PubMed ID: 38243885
[TBL] [Abstract][Full Text] [Related]
27. BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma.
Lee HE; Molina JR; Sukov WR; Roden AC; Yi ES
Hum Pathol; 2018 Sep; 79():168-176. PubMed ID: 29763720
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
[TBL] [Abstract][Full Text] [Related]
29. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
30. Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1.
Zaleski M; Kalhor N; Fujimoto J; Wistuba I; Moran CA
Pathol Res Pract; 2020 Dec; 216(12):153267. PubMed ID: 33176261
[TBL] [Abstract][Full Text] [Related]
31. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ
Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416
[TBL] [Abstract][Full Text] [Related]
32. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
[TBL] [Abstract][Full Text] [Related]
33. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.
Chapel DB; Hornick JL; Barlow J; Bueno R; Sholl LM
Mod Pathol; 2022 Oct; 35(10):1383-1397. PubMed ID: 35459788
[TBL] [Abstract][Full Text] [Related]
34. Genomic landscape of pleural and peritoneal mesothelioma tumours.
Hiltbrunner S; Fleischmann Z; Sokol ES; Zoche M; Felley-Bosco E; Curioni-Fontecedro A
Br J Cancer; 2022 Nov; 127(11):1997-2005. PubMed ID: 36138075
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.
Deraco M; Cabras A; Baratti D; Kusamura S
Ann Surg Oncol; 2015 Dec; 22(13):4344-51. PubMed ID: 25777091
[TBL] [Abstract][Full Text] [Related]
36. Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma.
Glass C; Sholl LM; Landgraf JR; Chirieac L; Roggli VL
Am J Surg Pathol; 2020 Feb; 44(2):288-292. PubMed ID: 31567203
[TBL] [Abstract][Full Text] [Related]
37. Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology.
Louw A; van Vliet C; Peverall J; Colkers S; Acott N; Creaney J; Lee YCG; Chai SM
Cancer Cytopathol; 2022 May; 130(5):352-362. PubMed ID: 35143119
[TBL] [Abstract][Full Text] [Related]
38. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
[TBL] [Abstract][Full Text] [Related]
39. Update of pathological diagnosis of pleural mesothelioma using genomic-based morphological techniques, for both histological and cytological investigations.
Nabeshima K; Hamasaki M; Kinoshita Y; Matsumoto S; Sa-Ngiamwibool P
Pathol Int; 2022 Aug; 72(8):389-401. PubMed ID: 35596704
[TBL] [Abstract][Full Text] [Related]
40. Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis?
Pulford E; Huilgol K; Moffat D; Henderson DW; Klebe S
Dis Markers; 2017; 2017():1310478. PubMed ID: 29085180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]